Clinical Study
Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors
Table 1
Demographics, HIV, and metabolic characteristics of the study population.
| | Characteristics | N | (%)/median (IQR) |
| | Age, median years (IQR) | 242 | 46 (40–54) | | <45 | 98 | (40.5) | | ≥45 | 144 | (59.5) | | Sex | | | | Male | 102 | (42.1) | | Female | 140 | (57.9) | | BMI, median kg/m² (IQR) | 242 | 22.3 (19.8–25.6) | | <25 | 174 | (71.9) | | ≥25 | 68 | (28.1) | | BMI at treatment initiation, median kg/m² (IQR) | 242 | 20.2 (18.4–22.6) | | <25 | 217 | (89.7) | | ≥25 | 25 | (10.3) | | CDC stage | | | | A | 16 | (6.6) | | B | 99 | (40.9) | | C | 127 | (52.5) | | HCV or HBV infection | 45 | (18.6) | | CD4 cell count, median cells/μL (IQR) | 242 | 501 (372–722) | | ≤200 | 13 | (5.4) | | >200 | 229 | (94.6) | CD4 cell count at treatment initiation,
median cells/μL (IQR) | 239 | 146 (61–229) | | ≤200 | 151 | (63.2) | | >200 | 88 | (36.8) | | HIV viral load < 50 copies/mL | 201 | (83.1) | | Total cholesterol (g/L) | | | | <1.5 | 224 | (92.6) | | ≥1.5 | 18 | (7.4) | | Triglycerides (g/L) | | | | <2.4 | 231 | (95.5) | | ≥2.4 | 11 | (4.5) |
|
|
IQR: interquartile range; BMI: body mass index; HCV: hepatitis C virus; HBV: hepatitis B virus.
|
